Abstract
Phase four of the Alzheimer’s Disease Neuroimaging Initiative (ADNI4) magnetic resonance imaging (MRI) protocols aim to maintain longitudinal consistency across two decades of data acquisition, while adopting new technologies. Here we describe and justify the study’s design and targeted biomarkers. The ADNI4 MRI protocol includes nine MRI sequences. Some sequences require the latest hardware and software system upgrades and are continuously rolled out as they become available at each site. The main sequence additions/changes in ADNI4 are: (1) compressed sensing (CS) T1-weighting, (2) pseudo-continuous arterial spin labeling (ASL) on all three vendors (GE, Siemens, Philips), (3) multiple-post-labeling-delay ASL, (4) 1 mm3 isotropic 3D fluid-attenuated inversion recovery, and (5) CS 3D T2-weighted. ADNI4 aims to help the neuroimaging community extract valuable imaging biomarkers and provide a database to test the impact of advanced imaging strategies on diagnostic accuracy and disease sensitivity among individuals lying on the cognitively normal to impaired spectrum.
Highlights
A summary of MRI protocols for phase four of the Alzheimer’s Disease Neuroimaging Initiative (ADNI 4).
The design and justification for the ADNI 4 MRI protocols.
Compressed sensing and multi-band advances have been applied to improve scan time.
ADNI4 protocols aim to streamline safety screening and therapy monitoring.
The ADNI4 database will be a valuable test bed for academic research.
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: Arvin Arani,
Bret Borowski,
John Felmlee,
Robert I. Reid,
David L. Thomas,
Jeffrey L. Gunter,
Lara Stables,
Randy L. Buckner,
Youngkyoo Jung,
Duygu Tosun,
Michael Weiner,
Clifford R. Jack Jr.,
for the Alzheimer’s Disease Neuroimaging Initiative | August 8, 2024